V
Vlasta Sýkorová
Publications - 7
Citations - 727
Vlasta Sýkorová is an academic researcher. The author has contributed to research in topics: Papillary thyroid cancer & Hazard ratio. The author has an hindex of 6, co-authored 7 publications receiving 528 citations.
Papers
More filters
Journal ArticleDOI
Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer
Mingzhao Xing,Ali S. Alzahrani,Kathryn A. Carson,Young Kee Shong,Tae Yong Kim,David Viola,Rossella Elisei,Bela Bendlova,Linwah Yip,Caterina Mian,Federica Vianello,R. Michael Tuttle,Eyal Robenshtok,James A. Fagin,Efisio Puxeddu,Laura Fugazzola,Agnieszka Czarniecka,Barbara Jarzab,Christine J. O'Neill,Mark Sywak,Alfred King-Yin Lam,Garcilaso Riesco-Eizaguirre,Pilar Santisteban,Hirotaka Nakayama,Roderick J. Clifton-Bligh,Giovanni Tallini,Elizabeth H. Holt,Vlasta Sýkorová +27 more
TL;DR: BRAF mutation was associated with poorer recurrence-free probability in Kaplan-Meier survival analyses in various clinicopathologic categories and demonstrated an independent prognostic value of BRAF V600E mutation for PTC recurrence in various clinical categories.
Journal ArticleDOI
Patient age-associated mortality risk is differentiated by BRAF V600E status in papillary thyroid cancer
Xiaopei Shen,Guangwu Zhu,Rengyun Liu,David Viola,Rossella Elisei,Efisio Puxeddu,Laura Fugazzola,Carla Colombo,Barbara Jarzab,Agnieszka Czarniecka,Alfred King-Yin Lam,Caterina Mian,Federica Vianello,Linwah Yip,Garcilaso Riesco-Eizaguirre,Garcilaso Riesco-Eizaguirre,Garcilaso Riesco-Eizaguirre,Pilar Santisteban,Pilar Santisteban,Christine J. O’Neill,Mark Sywak,Roderick J. Clifton-Bligh,Bela Bendlova,Vlasta Sýkorová,Mingzhao Xing +24 more
TL;DR: The results question the conventional general use of patient age as a high-risk factor in PTC and call for differentiation between patients with BRAF V600E and wild-type BRAF when applying age to risk stratification and management of PTC.
Journal ArticleDOI
The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.
Fei Wang,Fei Wang,Xiaolong Yu,Xiaolong Yu,Xiaopei Shen,Guangwu Zhu,Yueye Huang,Rengyun Liu,David Viola,Rossella Elisei,Efisio Puxeddu,Laura Fugazzola,Carla Colombo,Barbara Jarzab,Agnieszka Czarniecka,Alfred King-Yin Lam,Caterina Mian,Federica Vianello,Linwah Yip,Garcilaso Riesco-Eizaguirre,Pilar Santisteban,Christine J. O'Neill,Mark Sywak,Roderick J. Clifton-Bligh,Bela Bendlova,Vlasta Sýkorová,Yangang Wang,Shiguo Liu,Jiajun Zhao,Shihua Zhao,Mingzhao Xing +30 more
TL;DR: Tumor multifocality has no independent risk prognostic value in clinical outcomes of PTC; its indiscriminate use as an independent risk factor, prompting overtreatments of patients, should be avoided.
Journal ArticleDOI
BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.
Yueye Huang,Yueye Huang,Shen Qu,Guangwu Zhu,Fei Wang,Rengyun Liu,Xiaopei Shen,David Viola,Rossella Elisei,Efisio Puxeddu,Laura Fugazzola,Carla Colombo,Barbara Jarzab,Agnieszka Czarniecka,Alfred King-Yin Lam,Caterina Mian,Federica Vianello,Linwah Yip,Garcilaso Riesco-Eizaguirre,Garcilaso Riesco-Eizaguirre,Garcilaso Riesco-Eizaguirre,Pilar Santisteban,Pilar Santisteban,Christine J. O'Neill,Mark Sywak,Roderick J. Clifton-Bligh,Bela Bendlova,Vlasta Sýkorová,Mingzhao Xing +28 more
TL;DR: BRAF V600E identifies a subgroup of SI-PTC larger than 1.0 cm and 4.0″cm or less, that has high risk for recurrence comparable with that of invasive solitary PTC, making more aggressive treatment reasonable.
Journal ArticleDOI
BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer
Fei Wang,Fei Wang,Shihua Zhao,Xiaopei Shen,Guangwu Zhu,Rengyun Liu,David Viola,Rossella Elisei,Efisio Puxeddu,Laura Fugazzola,Carla Colombo,Carla Colombo,Barbara Jarzab,Agnieszka Czarniecka,Alfred King-Yin Lam,Caterina Mian,Federica Vianello,Linwah Yip,Garcilaso Riesco-Eizaguirre,Pilar Santisteban,Christine J. O'Neill,Mark Sywak,Roderick J. Clifton-Bligh,Bela Bendlova,Vlasta Sýkorová,Yangang Wang,Mingzhao Xing +26 more
TL;DR: Male sex is a robust independent risk factor for PTC-specific mortality in BRAF V600E patients but not in wild-type BRAF patients, and the prognostic risk of male sex in PTC can thus be stratified by BRAF status in clinical application.